Show simple item record

dc.contributor.authorLwin, S.M.; orcid: 0000-0002-3325-3675
dc.contributor.authorSnowden, J.A.; orcid: 0000-0001-6819-3476
dc.contributor.authorGriffiths, C.E.M.; orcid: 0000-0001-5371-4427; email: christopher.griffiths@manchester.ac.uk
dc.date.accessioned2021-07-28T05:22:34Z
dc.date.available2021-07-28T05:22:34Z
dc.date.issued2021-07-27
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625406/bjd.20517.xml?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625406/bjd.20517.pdf?sequence=3
dc.identifier.citationBritish Journal of Dermatology
dc.identifier.urihttp://hdl.handle.net/10034/625406
dc.descriptionFrom Wiley via Jisc Publications Router
dc.descriptionHistory: accepted 2021-05-18, pub-electronic 2021-07-27
dc.descriptionArticle version: VoR
dc.descriptionPublication status: Published
dc.descriptionFunder: NIHR Manchester Biomedical Research Centre; Id: http://dx.doi.org/10.13039/100014653
dc.description.abstractSummary: The management of moderate‐to‐severe psoriasis has been transformed by the introduction of biological therapies. These medicines, particularly those targeting interleukin (IL)‐17 and IL‐23p19, can offer clear or nearly clear skin for the majority of patients with psoriasis, with good long‐term drug survival. However, as currently used, none of these therapies is curative and disconcertingly there is a small but increasing number of patients with severe psoriasis who have failed all currently available therapeutic modalities. A similar scenario has occurred in other immune‐mediated inflammatory diseases (IMIDs) where treatment options are limited in severely affected patients. In these cases, cell therapy, including haematopoietic stem cell transplantation (HSCT) and mesenchymal stromal cells (MSC), has been utilized. This review discusses the various forms of cell therapy currently available, their utility in the management of IMIDs and emerging evidence for efficacy in severe psoriasis that is unresponsive to biological therapy. Balancing the risks and benefits of treatment vs. the underlying disease is key; cell therapy carries significant risks, costs, regulation and other complexities, which must be justified by outcomes. Although HSCT has anecdotally been reported to benefit severe psoriasis, sometimes with apparent cure, this has mainly been in the setting of other coincidental ‘routine’ indications. In psoriasis, cell therapies, such as MSC and regulatory T cells, with a lower risk of complications are likely to be more appropriate. Well‐designed controlled trials coupled with mechanistic studies are warranted if advanced cell therapies are to be developed and delivered as a realistic option for severe psoriasis.
dc.languageen
dc.rightsLicence for VoR version of this article: http://creativecommons.org/licenses/by-nc/4.0/
dc.sourceissn: 0007-0963
dc.sourceissn: 1365-2133
dc.subjectReview Article
dc.titleThe promise and challenges of cell therapy for psoriasis
dc.typearticle
dc.date.updated2021-07-28T05:22:33Z
dc.date.accepted2021-05-18


Files in this item

Thumbnail
Name:
bjd.20517.xml
Size:
7.899Kb
Format:
XML
Thumbnail
Name:
bjd.20517.pdf
Size:
815.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record